Treating Relapsed/Refractory Multiple Myeloma With Bispecific Therapy

Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab

During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.

Elranatamab Shows Efficacy of BCMA-Targeted Therapy in Multiple Myeloma

During a Targeted Oncology™ Case-Based Roundtable™ event, Mansi R. Shah, MD, discussed the impact of the MagnetisMM-1 and MagnetisMM-3 trials of elranatamab in patients with relapsed/refractory multiple myeloma. This is the second of 2 articles based on this event.

Teclistamab Shows Strong Efficacy in Triple-Refractory Multiple Myeloma

During a Targeted Oncology™ Case-Based Roundtable™ event, Mansi R. Shah, MD, discussed the impact of the MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. This is the first of 2 articles based on this event.

Manageable Toxicities Allow For Flexible Treatment in RRMM

In the second article of this 2-part series, Sikander Ailawadhi, MD, discusses how understanding the safety profile of the bispecific antibody teclistamab allows for physicians to treat and monitor their patients in a better way for them.

Targeting BCMA With Teclistamab Produces Impactful Results in RRMM

In the first article of a 2-part series, Sikander Ailawadhi, MD, looks at how the field has changed for treatment of patients with relapsed/refractory multiple myeloma and how recent study results with teclistamab show the impact of targeting BCMA in these patients.

Teclistamab Toxicities Highly Manageable in R/R Multiple Myeloma

In the second article of a 2-part series, Ajay Nooka, MD, MPH, discussed the exciting safety profile of teclistamab and how to manage major adverse events, like cytokine release syndrome, for patients with relapsed/refractory multiple myeloma.

Physicians Share Perceptions of BCMA-Targeted Therapies for Multiple Myeloma

During a Targeted Oncology™ Case-Based Roundtable™ event, Carol Ann Huff, MD, and other physicians discussed how they expect to use bispecific agents and CAR T-cell therapy in patients with relapsed/refractory multiple myeloma as the field advances.

Key Factors Influence Therapeutic Choices in Penta-Refractory Myeloma

During a Targeted Oncology™ Case-Based Roundtable™ event, Carol Ann Huff, MD, discussed the choice of therapy for a patient with relapsed/refractory multiple myeloma. This is is the first of 2 articles based on this event.

Bispecific T-Cell Engagers Improve Immune Response in Multiple Myeloma

Thomas G. Martin, MD, discusses the mechanism of action of bispecific T-cell engagers including teclistamab-cqyv in patients with relapsed/refractory multiple myeloma.

Managing Infections During Bispecific Therapy for Multiple Myeloma

Shaji Kumar, MD, discusses the incidence and management of infections in patients receiving teclistamab-cqyv or other bispecific agents for relapsed/refractory multiple myeloma.

Goals and Efficacy of the MajesTEC-1 Trial in Multiple Myeloma

Thomas G. Martin, MD, discusses the goals and efficacy outcomes of the phase 1/2 MajesTEC-1 trial of teclistamab-cqyv for patients with relapsed/refractory multiple myeloma.